세계의 결핵 진단 시장 규모, 점유율, 동향 분석 : 최종 용도별, 유형별, 지역별, 전망과 예측(2024-2031년)

Global Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By End Use (Diagnostic Laboratories, Hospitals & Clinics, and Others), By Type, By Regional Outlook and Forecast, 2024 - 2031

US $ 3,600 ￦ 5,206,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,320 ￦ 6,248,000

PDF (Multi User License)

PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,048 ￦ 8,747,000

PDF (Corporate User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

결핵 진단 시장 규모는 2031년까지 30억 달러에 달하며, 예측 기간 중 CAGR로 4.7%의 성장이 예측됩니다.

이 분야는 최근 수년간 결핵 검출의 정확성, 속도 및 접근성 향상에 크게 기여하는 중요한 기술 발전을 보였으며, GeneXpert MTB/RIF 분석은 결핵 치료를 변화시키는 분자진단의 가장 두드러진 사례 중 하나입니다. 따라서 이러한 요인들은 시장 성장을 가속할 것입니다.

그러나 첨단 결핵 진단 툴, 특히 분자진단을 기반으로 한 진단 툴은 중저소득 국가(LMIC)의 많은 의료 시스템에서 감당할 수 없는 가격인 경우가 많습니다. 또한 기부자 자금에 의존하는 것은 결핵 진단 자금 조달에 일정한 불확실성과 불안정성을 가져옵니다. 따라서 고급 결핵 진단 툴의 높은 비용과 자금의 한계와 불안정성이 결합되어 이러한 기술의 광범위한 도입에 큰 장벽이 되고 있습니다.

또한 COVID-19의 긴급한 요구에 대응하기 위해 결핵(TB) 대책에서 검사실 장비, 인력, 자금 배분 등의 자원이 전환되었습니다. 이는 전 세계 의료 시스템이 COVID-19 확진자 증가에 대응하지 못했으므로 이루어졌습니다. 이러한 자원의 전용으로 인해 많은 결핵 진단 시설이 COVID-19 검사로 전환되어 결핵 검사 및 진단이 크게 감소했습니다. 따라서 전염병은 시장에 전반적으로 부정적인 영향을 미쳤습니다.

최종 용도 전망

최종 용도에 따라 시장은 진단 실험실, 병원 및 클리닉, 기타로 분류됩니다. 병원 및 클리닉 부문은 2023년 시장에서 35%의 매출 점유율을 차지할 것으로 예상됩니다. 병원 및 클리닉은 많은 결핵 환자의 첫 번째 접촉점이기 때문에 초기 진단 및 치료 시작에 필수적입니다.

유형별 전망

유형에 따라 시장은 핵산 검사, 잠재적 감염 검출(피부 검사 및 IGRA), 약물 내성 검출(DST), 파지 분석, 사이토카인 검출 분석, 진단 검사 방법, 방사선 방법, 기타로 분류됩니다. 파지 분석 부문은 2023년 시장에서 18%의 매출 점유율을 차지할 것으로 예상됩니다. 박테리오파지를 사용하여 결핵균을 검출하는 이 방법은 신속하고 신뢰할 수 있는 결과를 제공할 수 있으므로 주목을 받고 있습니다.

지역 전망

지역별로 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 시장을 분석했습니다. 아시아태평양 부문은 2023년 시장에서 35%의 매출 점유율을 차지할 것으로 예상됩니다. 이 부문의 성장은 인도, 중국, 인도네시아와 같은 국가에서 결핵의 높은 부담에 의해 주도되고 있습니다. 이들 국가는 전 세계 결핵 환자 수의 상당 부분을 차지하므로 유비쿼터스 및 지속적인 결핵 진단의 구현이 필요합니다.

목차

제1장 시장 범위와 조사 방법

• 시장 정의
• 목적
• 시장 범위
• 세분화
• 조사 방법

제2장 시장 개관

• 주요 하이라이트

제3장 시장 개요

• 서론
  • 개요
    • 시장 구성과 시나리오
• 시장에 영향을 미치는 주요 요인
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장이 해결해야 할 과제
• Porter's Five Forces 분석

제4장 세계 시장 : 최종 용도별

• 세계의 진단 검사실 시장 : 지역별
• 세계의 병원·진료소 시장 : 지역별
• 세계의 기타 시장 : 지역별

제5장 세계 시장 : 유형별

• 세계의 잠재 감염 탐지(피부 테스트와 IGRA) 시장 : 지역별
• 세계의 파지 어세이 시장 : 지역별
• 세계의 약제 내성 탐지(DST) 시장 : 지역별
• 세계의 핵산 검사 시장 : 지역별
• 세계의 방사선법 시장 : 지역별
• 세계의 사이토카인 검출 어세이 시장 : 지역별
• 세계의 진단 검사법 시장 : 지역별
• 세계의 기타 방법 시장 : 지역별

제6장 세계 시장 : 지역별

• 북미
  • 북미의 시장 : 국가별
    • 미국
    • 캐나다
    • 멕시코
    • 기타 북미 지역
• 유럽
  • 유럽의 시장 : 국가별
    • 독일
    • 영국
    • 프랑스
    • 러시아
    • 스페인
    • 이탈리아
    • 기타 유럽 지역
• 아시아태평양
  • 아시아태평양의 시장 : 국가별
    • 중국
    • 일본
    • 인도
    • 한국
    • 싱가포르
    • 말레이시아
    • 기타 아시아태평양
• 라틴아메리카·중동 및 아프리카
  • 라틴아메리카·중동 및 아프리카의 시장 : 국가별
    • 브라질
    • 아르헨티나
    • 아랍에미리트
    • 사우디아라비아
    • 남아프리카공화국
    • 나이지리아
    • 기타 라틴아메리카·중동 및 아프리카 지역

제7장 기업 개요

• Abbott Laboratories
• Qiagen NV
• Thermo Fisher Scientific, Inc
• Becton, Dickinson, and Company
• F Hoffmann-La Roche Ltd.
• Hologic, Inc
• Danaher Corporation
• DiaSorin Sp.A
• Bruker Corporation
• Revvity, Inc

제8장 결핵 진단 시장의 성공 필수 조건

KSA

영문 목차

영문목차

The Global Tuberculosis Diagnostics Market size is expected to reach $3 billion by 2031, rising at a market growth of 4.7% CAGR during the forecast period.

Despite having a lower TB incidence than other regions, North America's market is driven by advanced healthcare systems, high levels of awareness, and strong public health initiatives focused on TB elimination. The U.S., in particular, has made significant investments in TB research and development, leading to the availability of cutting-edge diagnostic technologies. Consequently, the North American region would acquire nearly 30% of the total market share by 2031.

Tuberculosis (TB) continues to be a substantial global health issue, with a particularly high incidence rate in developing countries. The impact of TB is not confined to health alone; it also has significant social and economic consequences. Hence, the rising incidence of TB will increase the demand for diagnostics, thereby propelling the expansion of the market.

Additionally, this field has witnessed significant technological advancements in recent years, which have been crucial in enhancing the accuracy, speed, and accessibility of TB detection. The GeneXpert MTB/RIF assay is one of the most prominent examples of molecular diagnostics transforming TB care. Thus, these factors will aid in the growth of the market.

However, Advanced TB diagnostic tools, particularly those based on molecular diagnostics, are often priced beyond the reach of many healthcare systems in low- and middle-income countries (LMICs). The reliance on donor funding also introduces a level of uncertainty and instability in the financing of TB diagnostics. Hence, the high cost of advanced TB diagnostic tools, coupled with limited and unstable funding, presents significant barriers to the widespread adoption of these technologies.

Moreover, in order to meet the urgent needs of the pandemic, resources such as laboratory facilities, personnel, and financial allocations were redirected from tuberculosis (TB) initiatives. This was done because healthcare systems all over the world were unable to cope with the rise of COVID-19 cases. This diversion of resources led to a significant decline in TB testing and diagnosis, as many TB diagnostic facilities were repurposed for COVID-19 testing. Hence, the pandemic had an overall negative impact on the market.

End Use Outlook

On the basis of end use, the market is classified into diagnostic laboratories, hospitals & clinics, and others. The hospitals & clinics segment garnered 35% revenue share in the market in 2023. Hospitals and clinics serve as the first point of contact for many TB patients, making them critical for the initial diagnosis and treatment initiation.

Type Outlook

Based on type, the market is divided into nucleic acid testing, detection of latent infection (skin test & IGRA), detection of drug resistance (DST), phage assay, cytokine detection assay, diagnostic laboratory methods, radiographic method, and others. The phage assay segment procured 18% revenue share in the market in 2023. This method, which utilizes bacteriophages to detect TB bacteria, has gained traction due to its ability to provide quick and reliable results.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment procured a 35% revenue share in the market in 2023. The segment's growth is driven by the high burden of tuberculosis in countries such as India, China, and Indonesia. This necessitates the implementation of ubiquitous and continuous TB diagnostics, as these countries are responsible for a substantial proportion of the global TB case count.

List of Key Companies Profiled

• Abbott Laboratories
• Qiagen N.V
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• Bruker Corporation
• Revvity, Inc.

Global Tuberculosis Diagnostics Market Report Segmentation

By End Use

• Diagnostic Laboratories
• Hospitals & Clinics
• Others

By Type

• Detection of Latent Infection (Skin Test & IGRA)
• Phage Assay
• Detection of Drug Resistance (DST)
• Nucleic Acid Testing
• Radiographic Method
• Cytokine Detection Assay
• Diagnostic Laboratory Methods
• Other Methods

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Tuberculosis Diagnostics Market, by End Use
  • 1.4.2 Global Tuberculosis Diagnostics Market, by Type
  • 1.4.3 Global Tuberculosis Diagnostics Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges
• 3.3 Porter Five Forces Analysis

Chapter 4. Global Tuberculosis Diagnostics Market by End Use

• 4.1 Global Diagnostic Laboratories Market by Region
• 4.2 Global Hospitals & Clinics Market by Region
• 4.3 Global Others Market by Region

Chapter 5. Global Tuberculosis Diagnostics Market by Type

• 5.1 Global Detection of Latent Infection (Skin Test & IGRA) Market by Region
• 5.2 Global Phage Assay Market by Region
• 5.3 Global Detection of Drug Resistance (DST) Market by Region
• 5.4 Global Nucleic Acid Testing Market by Region
• 5.5 Global Radiographic Method Market by Region
• 5.6 Global Cytokine Detection Assay Market by Region
• 5.7 Global Diagnostic Laboratory Methods Market by Region
• 5.8 Global Other Methods Market by Region

Chapter 6. Global Tuberculosis Diagnostics Market by Region

• 6.1 North America Tuberculosis Diagnostics Market
  • 6.1.1 North America Tuberculosis Diagnostics Market by End Use
    • 6.1.1.1 North America Diagnostic Laboratories Market by Country
    • 6.1.1.2 North America Hospitals & Clinics Market by Country
    • 6.1.1.3 North America Others Market by Country
  • 6.1.2 North America Tuberculosis Diagnostics Market by Type
    • 6.1.2.1 North America Detection of Latent Infection (Skin Test & IGRA) Market by Country
    • 6.1.2.2 North America Phage Assay Market by Country
    • 6.1.2.3 North America Detection of Drug Resistance (DST) Market by Country
    • 6.1.2.4 North America Nucleic Acid Testing Market by Country
    • 6.1.2.5 North America Radiographic Method Market by Country
    • 6.1.2.6 North America Cytokine Detection Assay Market by Country
    • 6.1.2.7 North America Diagnostic Laboratory Methods Market by Country
    • 6.1.2.8 North America Other Methods Market by Country
  • 6.1.3 North America Tuberculosis Diagnostics Market by Country
    • 6.1.3.1 US Tuberculosis Diagnostics Market
      • 6.1.3.1.1 US Tuberculosis Diagnostics Market by End Use
      • 6.1.3.1.2 US Tuberculosis Diagnostics Market by Type
    • 6.1.3.2 Canada Tuberculosis Diagnostics Market
      • 6.1.3.2.1 Canada Tuberculosis Diagnostics Market by End Use
      • 6.1.3.2.2 Canada Tuberculosis Diagnostics Market by Type
    • 6.1.3.3 Mexico Tuberculosis Diagnostics Market
      • 6.1.3.3.1 Mexico Tuberculosis Diagnostics Market by End Use
      • 6.1.3.3.2 Mexico Tuberculosis Diagnostics Market by Type
    • 6.1.3.4 Rest of North America Tuberculosis Diagnostics Market
      • 6.1.3.4.1 Rest of North America Tuberculosis Diagnostics Market by End Use
      • 6.1.3.4.2 Rest of North America Tuberculosis Diagnostics Market by Type
• 6.2 Europe Tuberculosis Diagnostics Market
  • 6.2.1 Europe Tuberculosis Diagnostics Market by End Use
    • 6.2.1.1 Europe Diagnostic Laboratories Market by Country
    • 6.2.1.2 Europe Hospitals & Clinics Market by Country
    • 6.2.1.3 Europe Others Market by Country
  • 6.2.2 Europe Tuberculosis Diagnostics Market by Type
    • 6.2.2.1 Europe Detection of Latent Infection (Skin Test & IGRA) Market by Country
    • 6.2.2.2 Europe Phage Assay Market by Country
    • 6.2.2.3 Europe Detection of Drug Resistance (DST) Market by Country
    • 6.2.2.4 Europe Nucleic Acid Testing Market by Country
    • 6.2.2.5 Europe Radiographic Method Market by Country
    • 6.2.2.6 Europe Cytokine Detection Assay Market by Country
    • 6.2.2.7 Europe Diagnostic Laboratory Methods Market by Country
    • 6.2.2.8 Europe Other Methods Market by Country
  • 6.2.3 Europe Tuberculosis Diagnostics Market by Country
    • 6.2.3.1 Germany Tuberculosis Diagnostics Market
      • 6.2.3.1.1 Germany Tuberculosis Diagnostics Market by End Use
      • 6.2.3.1.2 Germany Tuberculosis Diagnostics Market by Type
    • 6.2.3.2 UK Tuberculosis Diagnostics Market
      • 6.2.3.2.1 UK Tuberculosis Diagnostics Market by End Use
      • 6.2.3.2.2 UK Tuberculosis Diagnostics Market by Type
    • 6.2.3.3 France Tuberculosis Diagnostics Market
      • 6.2.3.3.1 France Tuberculosis Diagnostics Market by End Use
      • 6.2.3.3.2 France Tuberculosis Diagnostics Market by Type
    • 6.2.3.4 Russia Tuberculosis Diagnostics Market
      • 6.2.3.4.1 Russia Tuberculosis Diagnostics Market by End Use
      • 6.2.3.4.2 Russia Tuberculosis Diagnostics Market by Type
    • 6.2.3.5 Spain Tuberculosis Diagnostics Market
      • 6.2.3.5.1 Spain Tuberculosis Diagnostics Market by End Use
      • 6.2.3.5.2 Spain Tuberculosis Diagnostics Market by Type
    • 6.2.3.6 Italy Tuberculosis Diagnostics Market
      • 6.2.3.6.1 Italy Tuberculosis Diagnostics Market by End Use
      • 6.2.3.6.2 Italy Tuberculosis Diagnostics Market by Type
    • 6.2.3.7 Rest of Europe Tuberculosis Diagnostics Market
      • 6.2.3.7.1 Rest of Europe Tuberculosis Diagnostics Market by End Use
      • 6.2.3.7.2 Rest of Europe Tuberculosis Diagnostics Market by Type
• 6.3 Asia Pacific Tuberculosis Diagnostics Market
  • 6.3.1 Asia Pacific Tuberculosis Diagnostics Market by End Use
    • 6.3.1.1 Asia Pacific Diagnostic Laboratories Market by Country
    • 6.3.1.2 Asia Pacific Hospitals & Clinics Market by Country
    • 6.3.1.3 Asia Pacific Others Market by Country
  • 6.3.2 Asia Pacific Tuberculosis Diagnostics Market by Type
    • 6.3.2.1 Asia Pacific Detection of Latent Infection (Skin Test & IGRA) Market by Country
    • 6.3.2.2 Asia Pacific Phage Assay Market by Country
    • 6.3.2.3 Asia Pacific Detection of Drug Resistance (DST) Market by Country
    • 6.3.2.4 Asia Pacific Nucleic Acid Testing Market by Country
    • 6.3.2.5 Asia Pacific Radiographic Method Market by Country
    • 6.3.2.6 Asia Pacific Cytokine Detection Assay Market by Country
    • 6.3.2.7 Asia Pacific Diagnostic Laboratory Methods Market by Country
    • 6.3.2.8 Asia Pacific Other Methods Market by Country
  • 6.3.3 Asia Pacific Tuberculosis Diagnostics Market by Country
    • 6.3.3.1 China Tuberculosis Diagnostics Market
      • 6.3.3.1.1 China Tuberculosis Diagnostics Market by End Use
      • 6.3.3.1.2 China Tuberculosis Diagnostics Market by Type
    • 6.3.3.2 Japan Tuberculosis Diagnostics Market
      • 6.3.3.2.1 Japan Tuberculosis Diagnostics Market by End Use
      • 6.3.3.2.2 Japan Tuberculosis Diagnostics Market by Type
    • 6.3.3.3 India Tuberculosis Diagnostics Market
      • 6.3.3.3.1 India Tuberculosis Diagnostics Market by End Use
      • 6.3.3.3.2 India Tuberculosis Diagnostics Market by Type
    • 6.3.3.4 South Korea Tuberculosis Diagnostics Market
      • 6.3.3.4.1 South Korea Tuberculosis Diagnostics Market by End Use
      • 6.3.3.4.2 South Korea Tuberculosis Diagnostics Market by Type
    • 6.3.3.5 Singapore Tuberculosis Diagnostics Market
      • 6.3.3.5.1 Singapore Tuberculosis Diagnostics Market by End Use
      • 6.3.3.5.2 Singapore Tuberculosis Diagnostics Market by Type
    • 6.3.3.6 Malaysia Tuberculosis Diagnostics Market
      • 6.3.3.6.1 Malaysia Tuberculosis Diagnostics Market by End Use
      • 6.3.3.6.2 Malaysia Tuberculosis Diagnostics Market by Type
    • 6.3.3.7 Rest of Asia Pacific Tuberculosis Diagnostics Market
      • 6.3.3.7.1 Rest of Asia Pacific Tuberculosis Diagnostics Market by End Use
      • 6.3.3.7.2 Rest of Asia Pacific Tuberculosis Diagnostics Market by Type
• 6.4 LAMEA Tuberculosis Diagnostics Market
  • 6.4.1 LAMEA Tuberculosis Diagnostics Market by End Use
    • 6.4.1.1 LAMEA Diagnostic Laboratories Market by Country
    • 6.4.1.2 LAMEA Hospitals & Clinics Market by Country
    • 6.4.1.3 LAMEA Others Market by Country
  • 6.4.2 LAMEA Tuberculosis Diagnostics Market by Type
    • 6.4.2.1 LAMEA Detection of Latent Infection (Skin Test & IGRA) Market by Country
    • 6.4.2.2 LAMEA Phage Assay Market by Country
    • 6.4.2.3 LAMEA Detection of Drug Resistance (DST) Market by Country
    • 6.4.2.4 LAMEA Nucleic Acid Testing Market by Country
    • 6.4.2.5 LAMEA Radiographic Method Market by Country
    • 6.4.2.6 LAMEA Cytokine Detection Assay Market by Country
    • 6.4.2.7 LAMEA Diagnostic Laboratory Methods Market by Country
    • 6.4.2.8 LAMEA Other Methods Market by Country
  • 6.4.3 LAMEA Tuberculosis Diagnostics Market by Country
    • 6.4.3.1 Brazil Tuberculosis Diagnostics Market
      • 6.4.3.1.1 Brazil Tuberculosis Diagnostics Market by End Use
      • 6.4.3.1.2 Brazil Tuberculosis Diagnostics Market by Type
    • 6.4.3.2 Argentina Tuberculosis Diagnostics Market
      • 6.4.3.2.1 Argentina Tuberculosis Diagnostics Market by End Use
      • 6.4.3.2.2 Argentina Tuberculosis Diagnostics Market by Type
    • 6.4.3.3 UAE Tuberculosis Diagnostics Market
      • 6.4.3.3.1 UAE Tuberculosis Diagnostics Market by End Use
      • 6.4.3.3.2 UAE Tuberculosis Diagnostics Market by Type
    • 6.4.3.4 Saudi Arabia Tuberculosis Diagnostics Market
      • 6.4.3.4.1 Saudi Arabia Tuberculosis Diagnostics Market by End Use
      • 6.4.3.4.2 Saudi Arabia Tuberculosis Diagnostics Market by Type
    • 6.4.3.5 South Africa Tuberculosis Diagnostics Market
      • 6.4.3.5.1 South Africa Tuberculosis Diagnostics Market by End Use
      • 6.4.3.5.2 South Africa Tuberculosis Diagnostics Market by Type
    • 6.4.3.6 Nigeria Tuberculosis Diagnostics Market
      • 6.4.3.6.1 Nigeria Tuberculosis Diagnostics Market by End Use
      • 6.4.3.6.2 Nigeria Tuberculosis Diagnostics Market by Type
    • 6.4.3.7 Rest of LAMEA Tuberculosis Diagnostics Market
      • 6.4.3.7.1 Rest of LAMEA Tuberculosis Diagnostics Market by End Use
      • 6.4.3.7.2 Rest of LAMEA Tuberculosis Diagnostics Market by Type

Chapter 7. Company Profiles

• 7.1 Abbott Laboratories
  • 7.1.1 Company Overview
  • 7.1.2 Financial Analysis
  • 7.1.3 Segmental and Regional Analysis
  • 7.1.4 Research & Development Expense
  • 7.1.5 SWOT Analysis
• 7.2 Qiagen N.V.
  • 7.2.1 Company Overview
  • 7.2.2 Financial Analysis
  • 7.2.3 Regional Analysis
  • 7.2.4 Research & Development Expenses
  • 7.2.5 Recent strategies and developments:
    • 7.2.5.1 Product Launches and Product Expansions:
  • 7.2.6 SWOT Analysis
• 7.3 Thermo Fisher Scientific, Inc.
  • 7.3.1 Company Overview
  • 7.3.2 Financial Analysis
  • 7.3.3 Segmental and Regional Analysis
  • 7.3.4 Research & Development Expenses
  • 7.3.5 Recent strategies and developments:
    • 7.3.5.1 Product Launches and Product Expansions:
  • 7.3.6 SWOT Analysis
• 7.4 Becton, Dickinson, and Company
  • 7.4.1 Company Overview
  • 7.4.2 Financial Analysis
  • 7.4.3 Segmental and Regional Analysis
  • 7.4.4 Research & Development Expense
  • 7.4.5 Recent strategies and developments:
    • 7.4.5.1 Partnerships, Collaborations, and Agreements:
  • 7.4.6 SWOT Analysis
• 7.5 F. Hoffmann-La Roche Ltd.
  • 7.5.1 Company Overview
  • 7.5.2 Financial Analysis
  • 7.5.3 Segmental and Regional Analysis
  • 7.5.4 Research & Development Expense
  • 7.5.5 Recent strategies and developments:
    • 7.5.5.1 Acquisition and Mergers:
  • 7.5.6 SWOT Analysis
• 7.6 Hologic, Inc.
  • 7.6.1 Company Overview
  • 7.6.2 Financial Analysis
  • 7.6.3 Segmental and Regional Analysis
  • 7.6.4 Research & Development Expenses
  • 7.6.5 SWOT Analysis
• 7.7 Danaher Corporation
  • 7.7.1 Company Overview
  • 7.7.2 Financial Analysis
  • 7.7.3 Segmental and Regional Analysis
  • 7.7.4 Research & Development Expense
  • 7.7.5 SWOT Analysis
• 7.8 DiaSorin S.p.A.
  • 7.8.1 Company Overview
  • 7.8.2 Financial Analysis
  • 7.8.3 Regional Analysis
  • 7.8.4 Research & Development Expenses
  • 7.8.5 SWOT Analysis
• 7.9 Bruker Corporation
  • 7.9.1 Company Overview
  • 7.9.2 Financial Analysis
  • 7.9.3 Segmental and Regional Analysis
  • 7.9.4 Research & Development Expense
  • 7.9.5 SWOT Analysis
• 7.10. Revvity, Inc.
  • 7.10.1 Company Overview
  • 7.10.2 Financial Analysis
  • 7.10.3 Segmental and Regional Analysis
  • 7.10.4 Research & Development Expenses
  • 7.10.5 SWOT Analysis

Chapter 8. Winning Imperatives for Tuberculosis Diagnostics Market

관련자료